Filing Flows

Filing Flows › ELI Lilly (LLY) › Next earnings date

ELI Lilly (LLY) earnings: beat the estimate

ELI Lilly (LLY) reported on Oct 29, 2026 and beat the EPS estimate: $7.48 against $6.35 (+17.9%). Revenue was $24.4B for Q3 2026, +39% year over year. It beat the EPS estimate in 100% of the quarters on record.

Last result+17.9% vs estimate
Beat rate100%

The last report

ELI Lilly reported revenue of $24.4B for the third quarter 2026 (+39% Y/Y), net earnings $6.5B: Net product revenue $22.7B, Other oncology $1.1B, Other immunology $579M. How it makes money → · Every quarter →

ELI Lilly: EPS against the estimate, last 5 reportsELI Lilly: EPS against the estimate, last 5 reportsEstimateReported$5.89$7.02Oct 25$6.91$7.54Feb 26$6.79$8.55Apr 26$6.58$8.38Aug 26$6.35$7.48Oct 26
Latest (Oct 26): Estimate $6.35, Reported $7.48.
LLY: the stock's move on each reportLLY: the stock's move on each reportAug 5, 2026+6.8%Apr 30, 2026+13.2%Feb 4, 2026+1.7%Oct 30, 2025+6.1%

ELI Lilly's latest quarter

ELI Lilly, Q3 2026: revenue $24.4B (+39% year over year), operating margin 34.5%, net earnings $6.5B, operating cash flow $11.4B. The chart follows the revenue to costs, profit and cash.

Questions

Did ELI Lilly beat earnings?

ELI Lilly (LLY) reported on Oct 29, 2026 and beat the EPS estimate: $7.48 against $6.35 (+17.9%).

When does LLY report earnings?

The next date is not set yet.

Does ELI Lilly usually beat earnings?

It beat the consensus EPS estimate in 100% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.